Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues (ANALUTS)
A Prospective Post Marketing Non Interventional Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive LHRH Analogues and to Evaluate the Effect of LHRH Analogues on Lower Urinary Tract Symptoms (ANALUTS Study)
Sponsor: Ipsen
A observational or N/A phase clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Ipsen and has accumulated 11 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Aug 2018 — Jan 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Nov 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Nov 2017 [monthly]
Recruiting NA
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Arganda, Spain , Badalona, Spain , Barcelona, Spain , Bilbao, Spain , Ciudad Real, Spain , Coimbra, Portugal , Getafe, Spain , L'Hospitalet de Llobregat, Spain , León, Spain and 17 more locations